Molecular Partners' DARPin platform shows promise, but future funding is uncertain. Learn why MOLN stock could be a risky, ...

Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Results From the Prospective BladderPath Trial Over the past 15 years, the landscape ...

"Our clients often tell us they choose Avance Clinical because of our hands-on, agile approach and the seamless integration we provide between early-phase trials in Australia and later-phase ...

SARASOTA, Fla. - Oragenics, Inc. (NYSE American: OGEN), a biotechnology firm focusing on brain health and infectious diseases ...

RA was well tolerated in the Phase I trial. Now MBX is planning a Phase II trial in post-bariatric hypoglycaemia patients.

ORIC-944 was initially evaluated as a single agent in a Phase 1b trial in patients with advanced prostate cancer and demonstrated potential best-in-class drug properties, including a clinical half ...

SGX301 has led positive results in early-stage CTCL, with over 70% achieving treatment success in the phase 3 FLASH study.

Topline results from a phase 2b/3 clinical trial of blarcamesine for individuals with early-stage Alzheimer’s disease showed ...

U.S.-based Prolium Biosciences has now agreed to pay InnoCare and Keymed $17.5 million in upfront and near-term payments to ...

ISM5411 was well tolerated and demonstrated a favourable pharmokinetic profile in validating gut-restrictive properties.

"Our clients often tell us they choose Avance Clinical because of our hands-on, agile approach and the seamless integration we provide between early-phase trials in Australia and later-phase trials in ...